Target intelligence / Profile preview

Senescence associated long non-coding RNA 3 (SALRNA3)

Target
SALRNA3
Molecular classification
Long non-coding RNA (lncRNA), Other (as it does not fit into protein-based families like receptor, ion channel, enzyme, transporter, but is classified as a regulatory RNA)
01

Overview

Senescence associated long non-coding RNA 3 (SALRNA3, XLOC_025918) is part of a subgroup of long non-coding RNAs whose expression levels change markedly during cellular senescence, particularly in human WI-38 fibroblasts. Silencing SALRNA3 in senescent fibroblasts prompts morphological changes and a decrease in cell numbers, consistent with increased apoptosis. Markers of apoptosis, such as cleaved PARP and elevated p53 levels, are also seen after SALRNA3 silencing. This suggests that SALRNA3 helps maintain survival in senescent cells. The specific downstream mediators and mechanistic partners of SALRNA3 remain unknown, and it has not yet been linked to any specific disease or therapeutic drug. Investigation into SALRNA1, SALRNA2, and SALRNA3 helps elucidate how lncRNAs can regulate the senescent phenotype and cell fate decisions, primarily influencing proliferation, apoptosis, and cell survival[3][1].

Other names
SAL-RNA3XLOC_025918SALRNA3
02

Biological functions

Cell survival (promotes survival of senescent cells)Regulation of apoptosis (interferes with apoptotic pathways in senescent cells)Cellular senescence (involved in regulating entry, maintenance, or survival of the senescent phenotype)
03

Disease associations

Other (potential relevance in aging through cellular senescence)Cancer (suggested by connection to apoptosis and cell survival, though direct disease associations have not been firmly established)

Beyond the preview

Go deeper on Senescence associated long non-coding RNA 3 (SALRNA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senescence associated long non-coding RNA 3 (SALRNA3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call